Literature DB >> 23999903

The modified Glasgow Prognostic Score (mGPS) is a good predictor of indication for palliative bypass surgery in patients with unresectable pancreatic and biliary cancers.

Yoshiaki Ikuta1, Hiroshi Takamori, Yasuo Sakamoto, Daisuke Hashimoto, Akira Chikamoto, Hideyuki Kuroki, Kazuya Sakata, Keita Sakamoto, Hiromitsu Hayashi, Katsunori Imai, Hidetoshi Nitta, Masahiko Hirota, Keiichiro Kanemitsu, Toru Beppu, Hideo Baba.   

Abstract

BACKGROUND: Patients with unresectable pancreatic and biliary cancers sometimes need decompression due to obstruction of the gastrointestinal tract and/or biliary tract. The aim of this study was to determine the prognostic factors associated with an indication for palliative bypass surgery in patients with unresectable pancreatic and biliary cancers.
METHODS: Between April 2005 and September 2011, 37 patients with unresectable pancreatic and biliary cancers underwent palliative bypass surgery. Prognostic factors were searched for among clinical characteristics, operation-related factors, and tumor-related factors using a prospective database.
RESULTS: The median survival time (MST) of these patients was 4.6 months, with a 6-month survival rate of 40.5 %. A multivariate Cox proportional hazards regression analysis revealed that mGPS >2 was the only independent prognostic factor for bypass surgery. Patients with an mGPS of 2 had an MST of 1.7 months, and they had a significantly worse prognosis than mGPS 0-1 patients with an MST of 6.3 months.
CONCLUSIONS: The mGPS is useful for predicting survival after surgical decompression due to gastrointestinal obstruction in patients with unresectable pancreatic and biliary cancers. Patients with a poor mGPS may not be indicated for palliative bypass surgery.

Entities:  

Mesh:

Year:  2013        PMID: 23999903     DOI: 10.1007/s10147-013-0613-y

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  31 in total

1.  Endoscopic metal stents for the palliation of malignant upper gastroduodenal obstruction.

Authors:  Hao-Tsai Cheng; Yung-Kuan Tsou; Cheng-Hui Lin; Chi-Liang Cheng; Jui-Hsiang Tang; Ching-Song Lee; Kai-Feng Sung; Mu-Hsien Lee; Jau-Min Len; Yin-Yi Chu; Ming-Hung Tsai; Nai-Jen Liu
Journal:  Hepatogastroenterology       Date:  2011 Nov-Dec

2.  The Glasgow Prognostic Score is a good predictor of treatment outcome in patients with unresectable pancreatic cancer.

Authors:  Mitsugi Shimoda; Masato Katoh; Junji Kita; Tokihiko Sawada; Keiichi Kubota
Journal:  Chemotherapy       Date:  2010-11-24       Impact factor: 2.544

3.  Evaluation of an inflammation-based prognostic score (GPS) in patients undergoing resection for colon and rectal cancer.

Authors:  Donald C McMillan; Joseph E M Crozier; Khalid Canna; Wilson J Angerson; Colin S McArdle
Journal:  Int J Colorectal Dis       Date:  2007-01-24       Impact factor: 2.571

4.  Glasgow Prognostic Score as a useful prognostic factor after hepatectomy for hepatocellular carcinoma.

Authors:  Kei Horino; Toru Beppu; Hideyuki Kuroki; Kosuke Mima; Hirohisa Okabe; Osamu Nakahara; Yoshiaki Ikuta; Akira Chikamoto; Takatoshi Ishiko; Hiroshi Takamori; Hideo Baba
Journal:  Int J Clin Oncol       Date:  2012-07-21       Impact factor: 3.402

5.  A comparison of POSSUM and GPS models in the prediction of post-operative outcome in patients undergoing oesophago-gastric cancer resection.

Authors:  Sumanta Dutta; Nesrin M Al-Mrabt; Grant M Fullarton; Paul G Horgan; Donald C McMillan
Journal:  Ann Surg Oncol       Date:  2011-03-24       Impact factor: 5.344

6.  Prognostic factors in the palliation of pancreatic cancer.

Authors:  F J F Engelken; V Bettschart; M Q Rahman; R W Parks; O J Garden
Journal:  Eur J Surg Oncol       Date:  2003-05       Impact factor: 4.424

7.  Evaluation of an inflammation-based prognostic score in patients with inoperable pancreatic cancer.

Authors:  Paul Glen; Nigel B Jamieson; Donald C McMillan; Ross Carter; Clem W Imrie; Colin J McKay
Journal:  Pancreatology       Date:  2006-07-13       Impact factor: 3.996

8.  The efficacy and safety of duodenal stenting: a prospective multicenter study.

Authors:  I Graber; R Dumas; B Filoche; J Boyer; D Coumaros; H Lamouliatte; J L Legoux; B Napoléon; T Ponchon
Journal:  Endoscopy       Date:  2007-09       Impact factor: 10.093

9.  Clinical utility of the Glasgow Prognostic Score in patients undergoing curative nephrectomy for renal clear cell cancer: basis of new prognostic scoring systems.

Authors:  G W A Lamb; M Aitchison; S Ramsey; S L Housley; D C McMillan
Journal:  Br J Cancer       Date:  2011-12-13       Impact factor: 7.640

10.  Evaluation of an inflammation-based prognostic score (GPS) in patients with metastatic breast cancer.

Authors:  A M Al Murri; J M S Bartlett; P A Canney; J C Doughty; C Wilson; D C McMillan
Journal:  Br J Cancer       Date:  2006-01-30       Impact factor: 7.640

View more
  6 in total

1.  Modified Glasgow prognostic score is an independent prognostic factor in patients with cervical cancer undergoing chemoradiotherapy.

Authors:  Yan Xiao; Ying-Kun Ren; Hui-Jun Cheng; Li Wang; Su-Xia Luo
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

2.  Clinical Value of Inflammation-Based Prognostic Scores to Predict the Resectability of Hyperbilirubinemia Patients with Potentially Resectable Hilar Cholangiocarcinoma.

Authors:  Hai-Jie Hu; Yan-Wen Jin; Rong-Xing Zhou; Wen-Jie Ma; Qin Yang; Jun-Ke Wang; Fei Liu; Nan-Sheng Cheng; Fu-Yu Li
Journal:  J Gastrointest Surg       Date:  2018-08-03       Impact factor: 3.452

3.  Inflammation-based prognostic scores and nutritional prognostic index in patients with locally-advanced unresectable colorectal cancer.

Authors:  Masahide Ikeguchi; Sho-Ichi Urushibara; Ryugo Shimoda; Manabu Yamamoto; Yoshihiko Maeta; Keigo Ashida
Journal:  World J Surg Oncol       Date:  2014-07-15       Impact factor: 2.754

4.  Clinical prognostic scores for patients with thymic epithelial tumors.

Authors:  Cecilia Veraar; Stefan Janik; Jürgen Thanner; Clarence Veraar; Mohamed Mouhieddine; Ana-Iris Schiefer; Leonhard Müllauer; Martin Dworschak; Walter Klepetko; Hendrik Jan Ankersmit; Bernhard Moser
Journal:  Sci Rep       Date:  2019-12-09       Impact factor: 4.379

5.  Efficacy of active hexose correlated compound on survival of patients with resectable/borderline resectable pancreatic cancer: a study protocol for a double-blind randomized phase II study.

Authors:  Daisuke Hashimoto; Sohei Satoi; Hideki Ishikawa; Yasuhiro Kodera; Keiko Kamei; Satoshi Hirano; Tsutomu Fujii; Kenichiro Uemura; Akihiko Tsuchida; Suguru Yamada; Tomohisa Yamamoto; Kiichi Hirota; Mitsugu Sekimoto
Journal:  Trials       Date:  2022-02-12       Impact factor: 2.279

6.  The systemic inflammation-based Glasgow Prognostic Score as a powerful prognostic factor in patients with upper tract urothelial carcinoma.

Authors:  Teruo Inamoto; Hideyasu Matsuyama; Shigeru Sakano; Naokazu Ibuki; Kiyoshi Takahara; Kazumasa Komura; Tomoaki Takai; Takuya Tsujino; Yuki Yoshikawa; Koichiro Minami; Kazuhiro Nagao; Ryo Inoue; Haruhito Azuma
Journal:  Oncotarget       Date:  2017-11-23
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.